Research Papers:

Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma

Ting Lu, Yan Liu, Shuang Yu, Congcong Yin, Peng Li, Jingjing Ye, Daoxin Ma and Chunyan Ji _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:56574-56583. https://doi.org/10.18632/oncotarget.10966

Metrics: PDF 1505 views  |   HTML 2255 views  |   ?  


Ting Lu1,*, Yan Liu1,*, Shuang Yu1, Congcong Yin1, Peng Li1, Jingjing Ye1, Daoxin Ma1, Chunyan Ji1

1Department of Hematology, Qilu Hospital, Shandong University, Jinan, PR China

*These authors contributed equally to this work

Correspondence to:

Chunyan Ji, email: [email protected]

Keywords: B-cell non-Hodgkin’s lymphoma, Th22, IL-22, prognosis

Received: November 23, 2015     Accepted: July 18, 2016     Published: July 30, 2016


T helper (Th) 22 cells play important roles in the pathogenesis of autoimmune and inflammatory diseases, and their function in tumors remains uncertain. In the current study, we investigated the alternations and clinical significance of circulating Th22 cells in patients with B-cell non-Hodgkin’s lymphoma (B-NHL). We found that the frequency of Th22 cells was significantly elevated in peripheral blood of newly-diagnosed B-NHL patients, and returned to normal level after chemotherapy. In consistent with increased Th22 frequency, plasma IL-22 and IL-6 levels in B-NHL patients were remarkably increased. Moreover, the increased Th22 frequency was associated with the older age (> 60 yr) and a poorer response to therapy in B-NHL patients. In addition, there existed a statistically positive correlation between circulating Th22 and Th17 frequencies in B-NHL patients. Our data demonstrated that circulating Th22 frequency was associated with the clinical outcome and prognosis of B-NHL patients, indicating that Th22 immune response might play an important role in the development and progression of B-NHL.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10966